Cargando…
Managing Drug Interactions With Oral Anticancer Treatments
The use of oral anticancer treatments is widespread and vital to modern cancer treatment. Novel oral chemotherapy and targeted therapy treatments continue to receive US Food and Drug Administration approval every year, making knowledge of these agents a necessity for practitioners working in oncolog...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414528/ https://www.ncbi.nlm.nih.gov/pubmed/37576366 http://dx.doi.org/10.6004/jadpro.2023.14.5.7 |
_version_ | 1785087356866396160 |
---|---|
author | Lohr, Lisa K. Blake, Kimball T. Chan, Cindy M. Sturm, Sabrina Walsh, Gavyn T. |
author_facet | Lohr, Lisa K. Blake, Kimball T. Chan, Cindy M. Sturm, Sabrina Walsh, Gavyn T. |
author_sort | Lohr, Lisa K. |
collection | PubMed |
description | The use of oral anticancer treatments is widespread and vital to modern cancer treatment. Novel oral chemotherapy and targeted therapy treatments continue to receive US Food and Drug Administration approval every year, making knowledge of these agents a necessity for practitioners working in oncology. Many oral anticancer agents are prone to drug interactions that can contribute to adverse effects and decrease therapy efficacy. Potential drug-drug interactions include (1) interactions with CYP3A4 inhibitors and inducers, (2) interactions related to gastric acid suppression, (3) interactions related to prolongation of the cardiac QT interval, (4) interactions related to anticoagulant medications, and (5) drug-food and drug-herb interactions. Identifying potential drug interactions and appropriately managing them is key to preventing adverse effects and ensuring maximum efficacy while on oral anticancer therapy. Management of adverse effects increases patient compliance, ensures medication safety, and allows patients to remain on therapy. This article discusses the mechanisms of interactions and types of interacting medications. Specific recommendations are discussed. |
format | Online Article Text |
id | pubmed-10414528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Harborside Press LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-104145282023-08-11 Managing Drug Interactions With Oral Anticancer Treatments Lohr, Lisa K. Blake, Kimball T. Chan, Cindy M. Sturm, Sabrina Walsh, Gavyn T. J Adv Pract Oncol Practice Matter The use of oral anticancer treatments is widespread and vital to modern cancer treatment. Novel oral chemotherapy and targeted therapy treatments continue to receive US Food and Drug Administration approval every year, making knowledge of these agents a necessity for practitioners working in oncology. Many oral anticancer agents are prone to drug interactions that can contribute to adverse effects and decrease therapy efficacy. Potential drug-drug interactions include (1) interactions with CYP3A4 inhibitors and inducers, (2) interactions related to gastric acid suppression, (3) interactions related to prolongation of the cardiac QT interval, (4) interactions related to anticoagulant medications, and (5) drug-food and drug-herb interactions. Identifying potential drug interactions and appropriately managing them is key to preventing adverse effects and ensuring maximum efficacy while on oral anticancer therapy. Management of adverse effects increases patient compliance, ensures medication safety, and allows patients to remain on therapy. This article discusses the mechanisms of interactions and types of interacting medications. Specific recommendations are discussed. Harborside Press LLC 2023-07 2023-07-01 /pmc/articles/PMC10414528/ /pubmed/37576366 http://dx.doi.org/10.6004/jadpro.2023.14.5.7 Text en © 2023 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Practice Matter Lohr, Lisa K. Blake, Kimball T. Chan, Cindy M. Sturm, Sabrina Walsh, Gavyn T. Managing Drug Interactions With Oral Anticancer Treatments |
title | Managing Drug Interactions With Oral Anticancer Treatments |
title_full | Managing Drug Interactions With Oral Anticancer Treatments |
title_fullStr | Managing Drug Interactions With Oral Anticancer Treatments |
title_full_unstemmed | Managing Drug Interactions With Oral Anticancer Treatments |
title_short | Managing Drug Interactions With Oral Anticancer Treatments |
title_sort | managing drug interactions with oral anticancer treatments |
topic | Practice Matter |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414528/ https://www.ncbi.nlm.nih.gov/pubmed/37576366 http://dx.doi.org/10.6004/jadpro.2023.14.5.7 |
work_keys_str_mv | AT lohrlisak managingdruginteractionswithoralanticancertreatments AT blakekimballt managingdruginteractionswithoralanticancertreatments AT chancindym managingdruginteractionswithoralanticancertreatments AT sturmsabrina managingdruginteractionswithoralanticancertreatments AT walshgavynt managingdruginteractionswithoralanticancertreatments |